
The Bond Market Is Revolting - Will There Be A Debt Crisis?
In 2013 President George W. Bush referred to the Greeks as 'Grecians'. At the time the 'mis-speaks' of the second Bush president provoked much amusement and some concern, though by comparison to the current occupant of the White House, the author of the disastrous invasion of Iraq is a strategic genius. The 'Grecians' came to mind this week when tuning into commentary by the Japanese prime minister Shigeru Ishiba who compared his country's fiscal situation to Greece in the early 2010's as he rejected calls for tax cuts. By the staid standard of Japanese political pronouncements this is controversial and will help draw attention to the rise in Japanese interest rates in the past two weeks.
Ishiba's comments are a harbinger of what is to come as we head into the 'Age of Debt', an era where indebtedness will dominate politics, economics and geopolitics. I have spent enough time in Greece over the years to know how brutally painful the consequences of austerity were, and how reckless economic policy had become in the late 1990's and early 2000's.
Indeed, I recall the late years of the (Andreas) Papandreou period, when the social debate in Athens revolved around his younger, second wife 'Mimi'. Papandreou was a very interesting character, and an example I often deploy to show that an education in economics is no guarantee of good policy – before he entered politics Papandreou was the Dean of the economics faculty at Stanford.
Often a finance minister will need political as well as policy skills. In his book, Stress Test, Tim Geithner, who was appointed Treasury Secretary by President Obama and who as head of the New York Fed had very good technical skills, worried aloud that he did not have the political skills for the role (arguably Robert Rubin was the master here) and the Obama team spent some time coaching him in this field.
There is a small but interesting literature on the backgrounds of finance ministers, which hypothesises that more left leaning governments (like Obama?) will choose economics experts to bolster their economic credibility, while right leaning governments often choose a finance minister with a financial services background – Donald Trump's two Treasury Secretaries, Steven Mnuchin (ex Goldman Sachs banker) and Scott Bessent (hedge fund manager who worked with George Soros for some time) fit this profile.
The point of my dragging up the cv's of finance ministers is to state that difficult times are ahead, and will require political courage and policy acumen, most of all in the US as President Trump takes aim at the budget deficit. Unfortunately, his lead policy manoeuvre on tariffs have shown that he has neither of these attributes.
In the US, President Trump has driven hard to have his budget (Big, Beautiful Bill) passed by Congress. It contains some elements that are quite sinister such as the ending of an excise tax on gun silencers, and one particular policy I agree strongly with – the introduction of MAGA (Money Account for Growth and Advancement), whereby the Treasury would create tax preferred savings accounts for children and give each one an initial deposit of USD 1,000. Europe should do the same!
However, the broad strokes of the budget look like they could rob many Americans of what they need most, notably MEDICAID. Worryingly from an economic point of view the budget is expected to add nearly USD 3.5 trillion to the budget deficit over the next ten years, according to a range of bodies from the Penn Wharton Budget Model to the Joint Committee on Taxation, and the implication is that the indebtedness of the US will rise further (estimates point to a historic debt to GDP ratio of 125% in ten years' time). The Congressional Budget Office publishes an intimidating chart that puts this in perspective and shows that the debt to GDP ratio in the US has only been higher (going all the way back to 1790) in the post-World War II period.
This is the daunting backdrop to two poor bond auctions last week (demand for US and Japanese bonds was well below the norm). In this respect, the case of Greece is instructive – notably the devastating effect of forced austerity, the difficulty in trying to make policy when a government has lost the confidence of markets and the reality that once this confidence is lost, it can take time to regain it.
Ultimately, Greece was a small economy in the scheme of things, though its membership of the euro made it systematically important. The US and Japan are on a different scale altogether.
We are all Grecians now.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
BOJ to be cautiously upbeat, keep rates steady as trade gloom lifts
By Leika Kihara TOKYO (Reuters) -The Bank of Japan is set to keep interest rates steady on Thursday and offer a cautiously optimistic view on the economic outlook, after Tokyo's trade deal with Washington cleared some uncertainty surrounding its fragile recovery. Markets are focusing on any hints Governor Kazuo Ueda may offer on the likelihood of another rate hike this year, as the central bank weighs lingering tariff-induced risks to growth and mounting inflationary pressure from higher food costs. "Given the high degree of uncertainty, I understand a wait and see stance is necessary for now," former BOJ Deputy Governor Hiroshi Nakaso told Reuters, warning U.S. tariffs and slowing global demand will weigh on Japan's economy. "But once the uncertainties clear enough for the BOJ to restore confidence that the economic and inflation trajectory will move in line with their projections, I think they will be back on their way to the next rate hike," he said. At the two-day meeting ending on Thursday, the BOJ is widely expected to keep short-term interest rates steady at 0.5%. In a quarterly report, the BOJ is likely to revise up this fiscal year's inflation forecast but maintain its view that underlying inflation - or price moves driven by domestic demand - remains short of its 2% target, sources have told Reuters. The BOJ may offer a less gloomy view on the economy compared with the current one focused on tariff-induced risks, but likely to warn of lingering uncertainty on how the higher U.S. levy affects business activity, separate sources said. "A weak real economy, a lack of demand-driven price pressure and lingering trade uncertainty will keep the central bank on hold," said Stefan Angrick, head of Japan and Frontier markets Economics at Moody's Analytics. "Our best guess is that the central bank will next hike rates in January, though a hike may come as early as December 2025," he said. A Reuters poll, taken before the Japan-U.S. trade deal announcement earlier this month, showed a majority of economists expect the BOJ to raise rates again by year-end. Japan's trade deal struck with President Donald Trump this month lowers U.S. tariffs for imports of goods including its mainstay automobiles, easing the pain for the export-reliant economy and clearing a key hurdle for further BOJ rate hikes. The positive development contrasts with the gloom that surrounded the economy on May 1, when the BOJ produced its current estimates amid heightened market volatility caused by Trump's April announcement of sweeping "reciprocal" tariffs. But the BOJ has not let its guard down yet. Deputy Governor Shinichi Uchida warned earlier this month that it was still hard to tell how much damage U.S. tariffs and slowing global trade could inflict on Japan's economy. The International Monetary Fund on Tuesday edged up its global growth forecast on front-loading demand from firms seeking to beat tariffs, but warned of major risks to the outlook including a potential rebound in tariffs. The key would be whether Japan's big manufacturers, which have been key drivers of wage hikes, will continue to increase pay as their profits get squeezed by U.S. tariffs, analysts say. The BOJ exited a decade-long, massive stimulus last year and raised its short-term policy rate to 0.5% in January on the view Japan was progressing towards durably achieving its price goal. While Governor Ueda has signaled a pause in rate hikes after Trump's April 2 announcement of "reciprocal" tariffs, Japan's trade deal with the U.S. has revived market expectations of an increase in its short-term policy rate to 0.75% by year-end. Some hawkish BOJ board members have stressed the need to pay more attention to upside risks to prices with stubbornly high food costs keeping core inflation above the bank's 2% target for well over three years. In current projections made on May 1, the BOJ projects core consumer inflation to hit 2.2% in fiscal 2025, before slowing to 1.7% in 2026 and 1.9% in 2027. Sign in to access your portfolio


Bloomberg
40 minutes ago
- Bloomberg
Japan Considers Tighter Oversight to Avoid Bond Market ‘Spoofing'
Japan's financial industry is looking to tighten oversight of trading in government bond futures, after Nomura Holdings Inc. joined a list of brokerages fined for manipulating the instruments. The Japan Securities Dealers Association and Japan Exchange Group Inc. are discussing ways to prevent a banned trade known as spoofing, their officials said, asking not to be identified because the matter is private. They are considering revising a guideline for reviewing trading in Japanese government bond futures and other derivatives, as well as offering more thorough training for financial firms, the officials added.
Yahoo
2 hours ago
- Yahoo
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase. The company reported earnings per American Depositary Share (EPADS) of 52 cents, surpassing analyst expectations of 47 cents. However, in yen terms, earnings per share (EPS) experienced a 14.1% decline, or a 10% decrease when adjusted for constant currency, reaching 151 yen. Total sales for the quarter amounted to $7.66 billion (1.11 trillion yen), exceeding consensus estimates of $7.53 billion. Despite this positive top-line performance, Takeda faced challenges on the bottom line, with core net profit dropping by 14.4% (or 10.3% at constant currency) to 237 billion key factor behind this decline was the significant erosion of revenue from Vyvanse, its attention-deficit hyperactivity disorder (ADHD) treatment, following the introduction of generic competition. This decline was anticipated by the company and was a major contributor to both the revenue drop and a reduction in core operating profit. View more earnings on TAK U.S. sales of Vyvanse fell 53.8% at constant exchange rates, dropping to 57.9 billion yen. The generics' market entry led to an overall sales decline of 46.9% for the drug during the quarter. On a more positive note, Takeda's portfolio of rare disease treatments showed resilience. Sales of Takhzyro, a treatment for hereditary angioedema, rose by 3.7% to 55.1 billion yen. Immunoglobulin sales also saw growth, increasing 2% at constant currency to 194 billion yen, while Albumin sales surged 16.2%, reaching 32.2 billion yen. In the vaccine segment, Takeda's Qdenga dengue vaccine experienced a 4.8% decline in sales at constant currency, amounting to 8.8 billion yen. However, the oncology division performed solidly, with Adcetris sales climbing 13.2% to 37.2 billion yen, while Fruzaqla, a novel therapy for certain cancers, saw a more modest growth of 8.9%, reaching 12.3 billion yen. Takeda's operating profit for the quarter rose 11% to 184.6 billion yen, while core operating profit dropped 15.8% (down 11.9% on a constant currency basis) to 321.8 billion yen. This decrease was primarily due to lower year-over-year impairment and restructuring expenses. Milano Furuta, Takeda's CFO, commented on the results, noting, 'The impact of Vyvanse generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May.' Outlook Takeda reaffirms its fiscal 2025 guidance, with core revenue of 4.53 trillion yen and core operating profit broadly flat at 1.14 trillion yen, and core earnings of 485 yen. Price Action: TAK stock is trading lower by 4.99% to $13.61 at last check Wednesday. Read Next:Photo by Veroniksha via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data